OBLN - Obalon Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.6775
-0.0025 (-0.37%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.6800
Open0.6400
Bid0.6714 x 1400
Ask0.6800 x 1800
Day's Range0.5311 - 0.6850
52 Week Range0.3700 - 3.7000
Volume5,855,612
Avg. Volume1,979,544
Market Cap15.892M
Beta (3Y Monthly)-1.52
PE Ratio (TTM)N/A
EPS (TTM)-1.6310
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.83
  • OBALON THERPTCS (OBLN) Stock Sinks As Market Gains: What You Should Know
    Zacks2 days ago

    OBALON THERPTCS (OBLN) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, OBALON THERPTCS (OBLN) closed at $0.68, marking a -0.37% move from the previous day.

  • Benzinga2 days ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • Benzinga3 days ago

    Obalon Management Takes Advantage Of 200% Rally, Announces $3M Offering

    Medical technology company Obalon Therapeutics Inc. (NASDAQ: OBLN ) announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common ...

  • GlobeNewswire3 days ago

    Obalon Therapeutics, Inc. Prices $3,000,000 Registered Direct Offering

    OBALON THERAPEUTICS, INC. (OBLN) (“Obalon” or the “Company”), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced it has entered into definitive agreements with investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $0.60 per share, pursuant to a registered direct offering.  The gross proceeds of the offering will be approximately $3,000,000 before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds for general corporate purposes, including, among other things, working capital, product development, capital expenditures, and other business opportunities.

  • GlobeNewswire5 days ago

    Expanded Clinical Data Set for the Obalon Balloon System Presented at DDW 2019

    SAN DIEGO, May 21, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • OBALON THERPTCS (OBLN) Dips More Than Broader Markets: What You Should Know
    Zacks9 days ago

    OBALON THERPTCS (OBLN) Dips More Than Broader Markets: What You Should Know

    OBALON THERPTCS (OBLN) closed the most recent trading day at $0.42, moving -1.96% from the previous trading session.

  • GlobeNewswire9 days ago

    Obalon Announces Receipt of Delisting Notification Letters from Nasdaq

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written notices from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") informing it that the Company is no longer in compliance with the Nasdaq Listing Rules. On May 15, 2019 the Company received a written notice from Nasdaq notifying the Company that it is not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) based on the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2019, which reported the Company’s stockholders’ equity as $6,518,000, which is below the minimum of $10,000,000 in stockholders’ equity required for continued listing.

  • Will OBALON THERPTCS (OBLN) Report Negative Q1 Earnings? What You Should Know
    Zacks24 days ago

    Will OBALON THERPTCS (OBLN) Report Negative Q1 Earnings? What You Should Know

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Obalon Engages Cowen to Explore Financial and Strategic Alternatives

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives.  As previously announced, Obalon recently undertook an organizational restructuring intended to refocus activities, streamline operations and make more efficient use of cash. With Cowen’s assistance, the Company plans to expand these efforts by exploring a wide range of financial and strategic alternatives that could enhance stockholder value and enable the Company to continue serving other important constituencies, including patients and physicians.

  • GlobeNewswire2 months ago

    Obalon Announces Restructuring to Streamline Operations & Cash Use

    The Company expects the restructuring to reduce operating expenses in the second quarter of 2019 by approximately 35%, after one-time charges of approximately $1.0 million, when compared to the first quarter of 2019.  The changes reduce overall headcount by approximately 50%, including the elimination of Obalon’s direct field sales force and a reduction of headquarters staff.  As a result, the Company expects to transition to a new selling model intended to efficiently use the existing resources to develop the market and drive revenue.  The Company plans to provide more details related to its revised commercial structure and strategy, in addition to expectations around key metrics and updated financial guidance, on its first quarter 2019 earnings call in May. Dr. Huang continued, “The swallowable, gas-filled Obalon Balloon System continues to perform very well clinically, and we have seen accounts that commit to making Obalon a priority in their practice achieve strong results.

  • GlobeNewswire2 months ago

    Obalon Announces Upcoming Conference Presentations

    SAN DIEGO, March 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire3 months ago

    Obalon Announces First Commercial Use of Navigation and Touch Products for Obalon Balloon Administration

    Obalon Therapeutics, Inc. (NASDAQ:OBLN) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve the reliability and ease of balloon administration, and to reduce the costs and logistics for physicians to adopt the Obalon Balloon System as a non-surgical treatment for their patients with obesity. Dr. Shawn Garber of New York Bariatric Group, who performed the first commercial administration using the Obalon Navigation System said, “We have made the Obalon Balloon a standard of care in my practice with outstanding outcomes for patients.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of OBLN earnings conference call or presentation 22-Feb-19 1:30pm GMT

    Q4 2018 Obalon Therapeutics Inc Earnings Call

  • OBALON THERPTCS (OBLN) Reports Q4 Loss, Lags Revenue Estimates
    Zacks3 months ago

    OBALON THERPTCS (OBLN) Reports Q4 Loss, Lags Revenue Estimates

    OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of -25.81% and -3.05%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire3 months ago

    Obalon Announces First Commercial Shipment of its Navigation Balloon Placement System with Touch Inflation Dispenser

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has begun commercial shipment of the Obalon Navigation System  with Touch Inflation Dispenser. Approved by the U.S. Food and Drug Administration in December 2018, the Company’s proprietary and patented Obalon Navigation System utilizes magnetic resonance, rather than x-ray radiation, to image the Obalon Balloon during placement with a dynamic, real-time image of the balloon on a tablet computer screen. The Obalon Touch Inflation Dispenser is designed specifically for use with the Obalon Navigation System to provide an automated, intuitive, and reliable solution for inflation once the balloon is properly placed in the patient’s stomach.

  • GlobeNewswire3 months ago

    Obalon Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN DIEGO, Feb. 22, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • ACCESSWIRE3 months ago

    Obalon Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 22, 2019 / Obalon Therapeutics, Inc. (NASDAQ: OBLN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 22, 2019 ...

  • How Many Insiders Bought Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?
    Simply Wall St.3 months ago

    How Many Insiders Bought Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...

  • GlobeNewswire3 months ago

    Obalon Schedules Fourth Quarter and Year End 2018 Financial Results Conference Call for February 22, 2019 at 8:30 a.m. Eastern Time

    SAN DIEGO, Feb. 15, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire5 months ago

    Obalon Announces Promotion of Amy VandenBerg to Chief Clinical & Regulatory Affairs Officer

    SAN DIEGO, Jan. 03, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire5 months ago

    Obalon to Host Call to Provide Update on Commercial Strategy Post FDA Approval of the Obalon Navigation System

    SAN DIEGO, Jan. 02, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire5 months ago

    Obalon Announces Promotion of Kelly Huang, Ph.D. To Chief Executive Officer

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today completed the succession plan previously announced with the promotion of Kelly Huang, Ph.D., to Chief Executive Officer. Dr. Huang has served as Obalon’s Chief Operating Officer since September 2017, and was promoted to President in August 2018. Andy Rasdal, who has served as CEO since Obalon’s founding in 2008 will serve as Executive Chairman.

  • ACCESSWIRE5 months ago

    Small Cap Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / December 28, 2018 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price ...

  • Benzinga5 months ago

    The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit a 52-week peak Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 27) • Aevi ...

  • GlobeNewswire5 months ago

    Obalon Therapeutics, Inc. Announces Two Agreements To Provide Up To $30 Million of Capital

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into two financing agreements that could enable the Company to access up to $30 million of capital. Obalon entered into a common stock purchase agreement and registration rights agreement (together, the “Agreements”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $20.0 million. Subject to the terms of the Agreements and following the filing and effectiveness of a registration statement, Obalon will have the right and the sole discretion to sell to LPC up to $20 million worth of shares over a 36-month period.  Obalon will control the timing and amount of any future investment and LPC will be obligated to make purchases in accordance with the Agreements and at a purchase price that is based on the then prevailing market prices of the Company’s shares at the time of each sale to LPC.  There are no upper limits to the price at which the shares may be sold to LPC.